0000950170-24-013959.txt : 20240212 0000950170-24-013959.hdr.sgml : 20240212 20240212170949 ACCESSION NUMBER: 0000950170-24-013959 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240208 FILED AS OF DATE: 20240212 DATE AS OF CHANGE: 20240212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brannan Stephen K. CENTRAL INDEX KEY: 0001777631 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38958 FILM NUMBER: 24621156 MAIL ADDRESS: STREET 1: C/O KARUNA THERAPEUTICS, INC. STREET 2: 33 ARCH STREET, SUITE 3110 CITY: BOSTON STATE: MA ZIP: 02110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karuna Therapeutics, Inc. CENTRAL INDEX KEY: 0001771917 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 270605902 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 857-449-2244 MAIL ADDRESS: STREET 1: 99 HIGH STREET STREET 2: 26TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 4 1 ownership.xml 4 X0508 4 2024-02-08 false 0001771917 Karuna Therapeutics, Inc. KRTX 0001777631 Brannan Stephen K. C/O KARUNA THERAPEUTICS, INC. 99 HIGH STREET, 26TH FLOOR BOSTON MA 02110 false true false false Chief Medical Officer true Common Stock 2024-02-08 4 M false 2500 5.45 A 41150 D Common Stock 2024-02-08 4 M false 5000 111.97 A 46150 D Common Stock 2024-02-08 4 S false 4182 316.05 D 41968 D Common Stock 2024-02-08 4 S false 818 316.56 D 41150 D Common Stock 2024-02-09 4 F false 1046 317.14 D 40104 D Option (right to buy) 5.45 2024-02-08 4 M false 2500 0 D 2027-06-01 Common Stock 2500 7177 D Option (right to buy) 111.97 2024-02-08 4 M false 5000 0 D 2032-02-16 Common Stock 5000 39604 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $315.50 to $316.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (3) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $316.51 to $316.70, inclusive. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the partial vesting of restricted stock units previously granted to the Reporting Person on February 9, 2023. This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter. This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of February 16, 2022, with additional vesting as to 6.25% of the shares underlying the option award at the end of each three month period thereafter. /s/ Mia Kelley, Attorney-in-Fact 2024-02-12